A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors

• Published in: Oncology Vol. 97; no. 2; p. 102
• Main Authors: Hong, David, Rasco, Drew, Veeder, Michael, Luke, Jason J, Chandler, Jason, Balmanoukian, Ani, George, Thomas J, Munster, Pamela, Berlin, Jordan D, Gutierrez, Martin, Mita, Alain, Wakelee, Heather, Samakoglu, Selda, Guan, Shanhong, Dimery, Isaiah, Graef, Thorsten, Borazanci, Erkut
• Format: Journal Article
• Language: English
• Published: Switzerland 01-07-2019
• Subjects: Adult; Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors; Aged; Aged, 80 and over; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasms - drug therapy; Prospective Studies; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - adverse effects; Pyrazoles - pharmacokinetics; Pyrazoles - therapeutic use; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; Pyrimidines - therapeutic use; Breast cancer; Phase 1b/2; Durvalumab; Pancreatic cancer; Ibrutinib; Non-small cell lung cancer
• ISSN: 1423-0232
• DOI: 10.1159/000500571

Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, is approved in the United States for the treatment of various B-cell malignancies. Preclinical data suggest synergistic antitumor activity of ibrutinib with programmed death-ligand 1 (PD-L1) inhibitors in solid tumors. This study evaluated ibrutinib plus durvalumab, a PD-L1-targeting antibody, in patients with relapsed/refractory solid tumors.
This open-label, multicenter, phase 1b/2 study enrolled previously treated patients with stage III/IV pancreatic adenocarcinoma, breast cancer, or non-small cell lung cancer (NSCLC). Phase 1b determined the recommended phase 2 dose (RP2D). In phase 2, patients were treated at the RP2D to evaluate the safety and antitumor activity of ibrutinib plus durvalumab.
The RP2D was identified as ibrutinib 560 mg p.o. daily and durvalumab 10 mg/kg i.v. every 2 weeks, with 122 patients treated at the RP2D. Median age was 61 years, and the majority of patients (94%) had stage IV disease. Overall response rates (complete or partial responses) were 2% for pancreatic cancer, 3% for breast cancer, and 0% for NSCLC. Median progression-free survival was 1.7, 1.7, and 2.0 months in the pancreatic cancer, breast cancer, and NSCLC cohorts, respectively. Median overall survival was 4.2, 4.2, and 7.9 months in the pancreatic cancer, breast cancer, and NSCLC cohorts, respectively. The safety profiles observed across tumor types were consistent with the known safety profiles for ibrutinib and durvalumab. Grade ≥3 adverse events in ≥5% of all patients were hyponatremia (10%), dyspnea (7%), maculopapular rash (7%), pneumonia (7%), anemia (6%), and diarrhea (6%).
The combination of ibrutinib 560 mg daily and durvalumab 10 mg/kg every 2 weeks had an acceptable safety profile. The antitumor activity of the ibrutinib-durvalumab combination was limited in our study population.